Ascorbic acid mitigates doxorubicin-induced spleen injury in rats: Histopathological and immunohistochemical insights

Basit Öğe Kaydı
dc.contributor.authorGezer, Arzu
dc.contributor.authorOzkaraca, Mustafa
dc.contributor.authorSari, Ebru Karadag
dc.contributor.authorBedir, Gursel
dc.contributor.authorAydin, Pelin
dc.contributor.authorAsker, Hasan
dc.contributor.authorAbd El-Aty, Am
dc.date.accessioned2024-10-26T18:02:23Z
dc.date.available2024-10-26T18:02:23Z
dc.date.issued2024
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractThis study assessed the protective potential of ascorbic acid against doxorubicin-induced spleen tissue damage in rats. Twenty-eight male Sprague-Dawley rats were divided into four groups. The control group received saline every other day at a dose of 1mL throughout the experiment. The ascorbic acid group was administered 50mg/kg of ascorbic acid daily for 10 days. The doxorubicin group received a single dose of 15mg/kg of doxorubicin on day 7. The ascorbic acid + doxorubicin group received both 50mg/kg of ascorbic acid daily for 10 days and a single dose of 15mg/kg of doxorubicin on day 7. After the experiment, splenic tissue samples were examined histopathologically and immunohistochemically. Histopathological analysis revealed edema, destruction, and degeneration in the doxorubicin group, but these changes were alleviated in the ascorbic acid-treated group, approaching control group levels. Immunohistochemical analysis showed increased CD4(+) and CD8(+) cell immunopositivity in the ascorbic acid + doxorubicin group compared to the doxorubicin group. Biochemical tests indicated that doxorubicin reduced superoxide dismutase activity and increased malondialdehyde levels, whereas ascorbic acid mitigated these effects. The findings suggest that ascorbic acid may have a protective role against doxorubicin-induced spleen injury in rats.
dc.identifier.doi10.36721/PJPS.2024.37.3.REG.591-599.1
dc.identifier.endpage599
dc.identifier.issn1011-601X
dc.identifier.issue3
dc.identifier.pmid39340850
dc.identifier.scopus2-s2.0-85205335442
dc.identifier.scopusqualityQ3
dc.identifier.startpage591
dc.identifier.urihttps://doi.org/10.36721/PJPS.2024.37.3.REG.591-599.1
dc.identifier.urihttps://hdl.handle.net/20.500.12418/28117
dc.identifier.volume37
dc.identifier.wosWOS:001252066200011
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherUniv Karachi
dc.relation.ispartofPakistan Journal of Pharmaceutical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAscorbic acid
dc.subjectCD4( +)
dc.subjectCD8( +)
dc.subjectspleen
dc.subjectdoxorubicin
dc.subjectsplenotoxicity
dc.titleAscorbic acid mitigates doxorubicin-induced spleen injury in rats: Histopathological and immunohistochemical insights
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu